Myeloproliferative Neoplasms (MPN)

CNL/atypical CML
- **IRB# 10262**
  - Oral Ruxolitinib for CNL or atypical CML.

Myelofibrosis
- **IRB# 16363**
  - Phase 2 INCB050465 plus Ruxolitinib
- **IRB# 15836**
  - Dual Syk/Jak inhibitor for myelofibrosis with JAK2 mutation

Systemic Mastocytosis
- **IRB# 17899**
  - Study Coming Soon

**IRB# 15977**
- Non Treatment National MDS Study (ECOG/ACRIN)

http://www.ohsu.edu/research/rda/so/knight.php